Tasman Health Care | Oncology Research

Research site

Location

Suite 1 Level 3 123 Nerang St, Southport, Queensland, Australia

Site insights

Top conditions

Top treatments

Darolutamide

Pembrolizumab

ERAS-254

IGM-8444

Xofigo

Androgen

Radium-223 Dichloride

Avelumab

Aplitibart

Trametinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

4 of 8 total trials

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2.Stage 2: To compare progression free survival (PFS) and over...

Enrolling

Advanced or Metastatic NRAS-mutant Melanoma

Drug: Trametinib

Drug: Naporafenib

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling

Biochemically Recurrent Prostate Cancer

Other: Placebo matching darolutamide

Drug: Darolutamide (BAY1841788, Nubeqa)

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Active, not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Drug: NAH therapy

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart...

Active, not recruiting

Solid Tumor

Chondrosarcoma

Drug: Docetaxel

Drug: Aplitabart (IGM-8444)

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms